• There is currently no approved reversal agent for factor Xa (FXa) inhibitors • Andexanet alfa has been developed to reverse the anticoagulant effects of FXa inhibitors • Andexanet reduced blood loss and anticoagulation markers in rivaroxaban-anticoagulated rabbits • Andexanet was well tolerated in monkeys and rats, with no evidence of prothrombotic activity Summary. Background: Andexanet alfa is a recombinant modified form of factor Xa (FXa), designed to bind to and reverse the anticoagulant activity of FXa inhibitors. Objectives: To evaluate the ability of andexanet to reverse the anticoagulant activity of rivaroxaban, and assess its pharmacokinetics (PK) and toxicity in animal models. Methods: The effects of andexanet on blood loss, anti-FXa activity, rivaroxaban unbound plasma concentrations and other coagulation parameters were assessed in a rabbit liver laceration 'treatment' model. Andexanet was administered 10 min after blood loss was initiated. The toxicity of repeated administration of andexanet (up to 60 mg kg À1 day À1 ) was assessed in cynomolgus monkeys.
Essentials
• There is currently no approved reversal agent for factor Xa (FXa) inhibitors • Andexanet alfa has been developed to reverse the anticoagulant effects of FXa inhibitors • Andexanet reduced blood loss and anticoagulation markers in rivaroxaban-anticoagulated rabbits • Andexanet was well tolerated in monkeys and rats, with no evidence of prothrombotic activity Summary. Background: Andexanet alfa is a recombinant modified form of factor Xa (FXa), designed to bind to and reverse the anticoagulant activity of FXa inhibitors. Objectives: To evaluate the ability of andexanet to reverse the anticoagulant activity of rivaroxaban, and assess its pharmacokinetics (PK) and toxicity in animal models. Methods: The effects of andexanet on blood loss, anti-FXa activity, rivaroxaban unbound plasma concentrations and other coagulation parameters were assessed in a rabbit liver laceration 'treatment' model. Andexanet was administered 10 min after blood loss was initiated. The toxicity of repeated administration of andexanet (up to 60 mg kg À1 day À1 ) was assessed in cynomolgus monkeys.
PK parameters were evaluated in rats and monkeys. Results: Excess blood loss due to anticoagulation with rivaroxaban was significantly decreased by a single intravenous bolus administration of andexanet at 35 and 75 mg per rabbit, by 75% and 63%, respectively. This correlated with dose-dependent decreases in the unbound fraction of rivaroxaban and anti-FXa activity. Co-administration of rivaroxaban had no significant impact on the PK parameters of andexanet. Andexanet (up to 60 mg kg À1 day À1 ) was well tolerated in monkeys, with no accumulation of andexanet or rivaroxaban. There was a single occurrence of anaphylaxis, which resolved after treatment with diphenhydramine and epinephrine. There was no histological evidence of prothrombotic activity with high-dose andexanet compared with vehicle control, as measured by clot and fibrin deposition in all major organs. Conclusions: These data suggest that andexanet is
Introduction
Direct oral anticoagulants, including factor Xa (FXa) inhibitors, are being rapidly adopted and are included in international treatment guidelines for atrial fibrillation (AF) [1, 2] and venous thromboembolism [3] [4] [5] . All anticoagulants are associated with a risk of bleeding, and rapid reversal of anticoagulant effects may be needed in clinical situations such as the management of severe, life-threatening bleeding events or if urgent high-bleeding-risk surgery is required [1, [6] [7] [8] . At this time, there are no specific approved reversal agents for FXa inhibitors, including rivaroxaban. Andexanet alfa is a recombinant protein designed to act as a universal antidote to FXa inhibitors. It is a modified form of FXa that competes with native FXa for binding FXa inhibitors, with subnanomolar affinities similar to those of the native molecule, counteracts their anticoagulant activity, but is catalytically inactive and no longer capable of assembly in the prothrombinase complex [9] . Andexanet is expressed in its mature, functional form in Chinese hamster ovary cells, bypassing the need for its activation through intrinsic or extrinsic pathways of coagulation [9] . Additionally, it has been demonstrated both in vitro and in vivo that andexanet does not interfere with normal FXa function in hemostasis, nor does it have anticoagulant or prothrombotic activity [9] .
Onset of action of andexanet is rapid, resulting in sequestration of the anticoagulant and a rapid restoration of FXa catalytic activity. In addition to rapidly binding plasma anticoagulant, andexanet also causes a pharmacokinetic (PK) redistribution of the direct FXa inhibitor from the extravascular compartment to the intravascular compartment, where it is also sequestered by andexanet [9] . Dose-dependent reversal of the anti-FXa activity of rivaroxaban, apixaban and betrixaban has been demonstrated in a rat model, with a corresponding decrease in the plasma 'free' (unbound) fraction of the inhibitor. Andexanet has also been shown to reduce blood loss when administered prophylactically in mouse and rabbit models, with correlating decreases in the unbound fraction of rivaroxaban and reduction in anti-FXa activity [9] . Furthermore, andexanet reversed the anticoagulant activity of the antithrombin-dependent FXa inhibitors enoxaparin and fondaparinux in a rat model [9] .
In previously published animal models, andexanet was administered prior to initiation of blood loss [9] . To more closely reflect the scenario in which andexanet would potentially be used in clinical practice, we investigated its ability to mitigate blood loss when administered after initiation of liver injury and blood loss in rivaroxaban-administered rabbits. In addition, we characterized andexanet in terms of its effectiveness in rabbits and its safety and tolerability in the rat and monkey in Good Laboratory Practice (GLP) studies.
Methods

Animal models and treatments
For the liver laceration model, New Zealand white male rabbits (Charles River, Saint-Constant, QC, Canada) were used. For the anticoagulation model and toxicokinetic analysis, Sprague Dawley male rats (Charles River, Hollister, CA, USA) were used. Additional toxicology analyses were performed in cynomolgus monkeys (Covance Research Products, Madison, WI, USA). No animals were replaced and all were consecutively included. All procedures were approved by Portola Pharmaceuticals' Institutional Animal Care and Use Committee, and conducted in accordance with the Guide for the Care and Use of Laboratory Animals.
Andexanet vehicle was 10 mM Tris (pH 7.8), 95 mM L-Arg HCl, 4% Sucrose and 0.01% Tween 80. Rivaroxaban vehicle was 85% PEG300, 8% H 2 O, 5% glycerin and 2% DMSO.
Plasma concentrations and coagulation assays
Total rivaroxaban concentration was measured by highperformance liquid chromatography with tandem mass spectrometry (HPLC-MS/MS). The fraction of rivaroxaban not bound to plasma proteins or andexanet was determined by ultrafiltration, followed by HPLC-MS/MS.
Andexanet and hEGR-Xa (human FXa with active site inhibited irreversibly by Glu-Gly-Arg chloromethyl ketone) plasma concentrations were determined by an enzyme-linked immunosorbent assay (ELISA) with paired antibodies recognizing human FX/FXa (FX-EIA, Enzyme Research Laboratories, South Bend, IN, USA) [9] . To determine pharmacokinetic parameters, andexanet plasma concentration was analyzed by non-compartmental analysis using WinNonlin software (Version 5.3, Pharsight Corp., Cary, NC, USA) or Watson software (Version 7.3, Thermo Corp., Philadelphia, PA, USA).
Plasma concentrations of thrombin-antithrombin (TAT) complex and fibrin degradation product (D-dimer) were determined by ELISA using Enzygno Ò TAT micro (Siemens, USA, Newark, DE, USA) and Asserachrom D-Di (Diagnostica Stago, Parsippany, NJ, USA) kits according to the manufacturers' instructions. Anti-FXa activity was measured using reagents from a commercial heparin kit (Coamatic, Heparin, DiaPharma, Wester Chester, OH, USA) as previously described [9] . The assay set-up was modified to minimize the effect of sample dilution on the reversal activity of andexanet. In a rabbit model, prothrombin time (PT) and activated partial thromboplastin time (APTT) were measured using ACL Elite and HemosIL reagents (Instrumentation Laboratory, Bedford, MA, USA) according to the manufacturer's instructions. In a rat anticoagulation model, PT and APTT were measured using an Electra 800 Automatic Coagulation Timer (Medical Laboratory Automation, Pleasantville, NY, USA), using Dade Thromboplastin C Plus (Siemens, Newark, DE, USA) and Dade Actin FS Activated PTT (Siemens) reagents, according to standard operating procedure.
Rabbit liver laceration treatment model
In a modified rabbit liver laceration treatment model [9] , animals were administered vehicle (n = 10) or rivaroxaban (0.5 mg kg À1 ) by i.v. bolus (marginal ear vein), 30 min prior to liver injury. A standardized liver laceration injury of two liver lobes was performed with a scalpel blade (five times in each lobe; each incision 1 cm long, 2-3 mm deep) and allowed to bleed for 10 min onto pre-weighed gauze. The blood-soaked gauze was replaced with a clean pre-weighed gauze and andexanet (5, 15, 35 or 75 mg per rabbit; n = 7/group) or vehicle (n = 15) was administered (i.v. bolus via marginal ear vein catheter) at a rate of 5 mL min À1 over 5 min. After 30 min, the gauze was weighed to determine blood loss. Plasma samples were collected at 0, 30, 40, 45, 60 and 75 min after rivaroxaban administration to measure the concentrations of rivaroxaban (total and unbound) and andexanet, anti-FXa activity and coagulation parameters (Fig. 1A) .
Rat tail transection model
Rats were anesthetized and the right jugular and left femoral veins catheterized for andexanet administration and serial blood sampling (at 0, 5, 10 and 25 min). At 0 min, rats were administered a bolus injection of normal saline via the jugular vein catheter (to simulate the procedure from previous experiments where an anticoagulant was given). At 5 min, 4 mg andexanet or vehicle was administered by i.v. bolus over 5 min (n = 4/group). Blood loss was initiated at 10 min with the transection of the tail 2-3 mm from the tip with a scalpel blade, immersed in normal saline at 37°C. The transection was immediately followed by a 15-min andexanet or vehicle infusion (4 mg h À1 ) and continuous collection of blood.
Blood samples were frozen at À80°C to lyse erythrocytes. Hemoglobin concentration and blood volume were quantified spectrophotometrically (absorbance at 490 nm) from a standard curve constructed with known volumes of blood.
Co-administration of andexanet with hEGR-Xa in a rat anticoagulation model
The right jugular vein and left and right femoral veins of anesthetized rats were catheterized for hEGRXa and andexanet administration, and serial blood samples were obtained. Animals were administered (90-min infusion) hEGR-Xa (Haemotologic Technologies, Essex Junction, VT, USA) at 0.5 or 1.0 mg kg À1 h À1 (or vehicle) [10] . Forty-five minutes after the start of hEGR-Xa infusion, andexanet bolus (1 mg over 2 min) followed by infusion (1.5 mg h À1 over 43 min) or vehicle was administered (n = 4/group). hEGR-Xa and andexanet infusions were discontinued after the 90-min blood sample. Toxicokinetic analysis of andexanet in rats
Rats were administered 1 mg kg À1 rivaroxaban or rivaroxaban vehicle orally (p.o.), 1 h prior to andexanet administration (n = 4/group). For assessing PK parameters, 1 mg andexanet was administered (i.v. bolus over 5 min); blood samples were collected pre-dose and for up to 23 h post-dose. For assessing the effect of repeat doses of andexanet on rivaroxaban renal excretion, four successive doses of andexanet (2 mg initial dose followed by three 1-mg doses at 30-min intervals) or vehicle were administered; blood samples were collected pre-dose and for up to 24 h post-dose. For evaluating the extent of renal elimination of andexanet, rats underwent either no surgery (control), sham operation or unilateral or bilateral nephrectomy; andexanet (3 mg kg À1 ) was administered by i.v. bolus approximately 1 h after anesthetic recovery post-surgery; blood samples were collected predose and up to 8 h post-dose.
Toxicology study of andexanet in cynomolgus monkeys
In a GLP toxicology study, cynomolgus monkeys (n = 5/ gender/group) were administered andexanet or vehicle (alone or in combination with rivaroxaban ) twice daily (~4 h apart), every 3 days for 13 days, administered~4 h after each rivaroxaban dose (the approximate C max [maximum drug concentration in plasma] of rivaroxaban in plasma). In the main study phase, six animals (n = 3/gender) per dosing group were euthanized and necropsied on day 14; the remaining animals were further monitored for 28 days (recovery phase) and then euthanized and necropsied. Assessment of toxicity was based on clinical observations, bodyweight, body temperature, ophthalmic examinations, electrocardiogram evaluations, blood pressure determinations, antidrug antibody analysis and histopathology. Blood samples were collected for PK evaluation, clinical chemistry, hematology and coagulation assays (PT, APTT and Russell's viper venom time [RVVT]). Histology was performed using hematoxylin and eosin (H&E) and phosphotungstic acid hematoxylin (PTAH) staining.
Statistical analyses
Data are reported as mean AE standard deviation. Data from the rabbit liver laceration model, rat anticoagulation model and rat tail transection model were analyzed by Student's unpaired t-test comparing each treatment group with the vehicle control group (two-tail distribution) with Levene's test for equality of variances. Data from the monkey toxicity study were evaluated separately for each gender using one-way analysis of variance (ANOVA) and Fisher's least significant difference t-test for pairwise comparisons between each treated and control group. A P-value ≤0.05 was considered statistically significant.
Results
Restoration of hemostasis in a rabbit liver laceration treatment model
Effect of andexanet on blood loss Administration of rivaroxaban significantly increased mean blood loss bỹ 3-fold compared with non-anticoagulated (vehicle + vehicle) rabbits (P < 0.001; Fig. 1B) . Following liver injury, administration of 75 or 35 mg andexanet (rivaroxaban + andexanet) significantly decreased blood loss by 63% and 75%, respectively, compared with rivaroxaban + vehicle (P < 0.05); decreases in blood loss following 15 or 5 mg andexanet (16% and 12%, respectively) were not statistically significant (Fig. 1B) . In rabbits receiving rivaroxaban + andexanet, total rivaroxaban plasma concentration increased after administration of andexanet in a dose-dependent manner ( Fig. 2A) , reaching a plateau at~4 lM ( Figure S1A andexanet showed increases of~4-fold and~2-fold, respectively ( Fig. 2A ).
Plasma concentrations of rivaroxaban and andexanet
There was a corresponding dose-dependent decrease in unbound rivaroxaban plasma concentration following andexanet administration (Fig. 2B) . Immediately after andexanet bolus, the average percent unbound (relative to total) rivaroxaban plasma concentration decreased in a dose-dependent manner (99.9%, 95.1%, 67.0% and 21.6% following 75, 35, 15 and 5 mg andexanet, respectively) compared with rivaroxaban + vehicle.
Anti-FXa activity Administration of andexanet resulted in a dose-dependent decrease in anti-FXa activity (Fig. 2C) . Immediately after andexanet bolus, mean antiFXa activity in rivaroxaban-anticoagulated animals was reduced by 99%, 96.6%, 75% and 46.7% following 75, 35, 15 and 5-mg doses, respectively. The reduction in anti-FXa activity by ≥ 90% was achieved with a 1.3 : 1 stoichiometric ratio of andexanet to rivaroxaban concentration ( Figure S1B ). There was a positive correlation between the anti-FXa activity and unbound rivaroxaban concentration (R 2 = 0.992) ( Figure S1C ).
Markers of anticoagulation activity Following andexanet administration, there was a dose-dependent reduction in rivaroxaban-induced prolongation of PT ( Figure S2A ) and APTT ( Figure S2B ). Immediately after the 5-min bolus, PT values were reduced by 91%, 81%, 45% and 12% with the 75, 35, 15 and 5-mg dose, respectively, compared with baseline values. Similarly, APTT values were reduced by 85%, 64%, 26% and 10%, respectively.
Pharmacokinetic characterization of andexanet in the presence or absence of rivaroxaban
Plasma concentration-time profiles of andexanet can be described by a two-compartment model, containing distribution and elimination phases with distinct half-lives. Overall, the mean systemic clearance is low, with a small volume of distribution at steady state, which is approximately equivalent to the sum of the blood volume plus the extravascular volume in rat and monkey models. Andexanet has a short distribution half-life in both species, followed by a long terminal half-life (Table 1) . Plasma C max and AUC(0-∞) were similar on days 1 and 13 in cynomolgus monkeys administered andexanet twice daily, every third day, suggesting no accumulation (Table 1) . In rats, co-administration of rivaroxaban did not have a significant impact on andexanet PK parameters, including clearance (Table 1; Figure S3 ).
Administration of four successive doses of andexanet 30 min apart did not have an effect on rivaroxaban elimination rate in rats. Rivaroxaban plasma concentrations at 6 h post-dose were similar in the presence or absence of andexanet, and declined at the same rate (data not shown). Renal clearance of rivaroxaban was not altered by andexanet ( Figure S4 ). In animals receiving rivaroxaban alone, the cumulative percent dose of unchanged rivaroxaban excreted into urine over a 24-h period was 4.5%, compared with 5.3% when co-administered with andexanet. This is in line with previously published data on the metabolism and excretion of rivaroxaban [11] . The systemic clearance of andexanet decreased by 29.4% and 50.6% in unilateral and bilateral nephrectomized rats, respectively, compared with rats that underwent sham operation (data not shown).
Preclinical safety studies with andexanet
Co-administration of andexanet with hEGR-Xa (rat anticoagulation model) To demonstrate differences between andexanet and an active-site inactivated form of human FXa (hEGR-Xa) and confirm that andexanet had no anticoagulant activity on its own, we carried out experiments in rats that were administered andexanet alone, hEGR-Xa, or andexanet + hEGR-Xa. After co-administration of andexanet + hEGR-Xa (at a ratio of 10 : 1), andexanet mean plasma concentrations were~10-fold higher compared with those for hEGR-Xa. Under these conditions, andexanet did not demonstrate any anticoagulant activity when administered alone or with hEGR-Xa. Administration of andexanet alone did not result in significant changes in PT and APTT compared with vehicle ( Figure S5 ). Also, there were no significant changes in PT and APTT in rats administered hEGR-Xa alone compared with co-administration with andexanet ( Figure S5 ).
Effect of andexanet alone on blood loss (rat tail transection model) Andexanet did not demonstrate a procoagulant activity in non-anticoagulated animals. At plasma concentrations between 3.8 lM (after bolus administration) and 2.4 lM (end of experiment), andexanet did not significantly affect blood loss compared with vehicle controls. Mean blood loss for the vehicle and andexanet groups was 65 AE 24 and 63 AE 21 lL, respectively (P = 0.92). ), resolving with administration of diphenhydramine and epinephrine, in one male on day 13.
Toxicity in cynomolgus monkeys
No abnormal observations were made on bodyweight, body temperature, ophthalmic observations, Table 1 Mean pharmacokinetic parameters for andexanet derived from toxicology studies in rats and monkeys Animal Dose of andexanet AUC, area under the plasma concentration-time curve; CL, systemic clearance; C max , maximum drug concentration in plasma; T 1/2 , half-life; Vss, volume of distribution at steady-state. *Andexanet administered by i.v. infusion over 5 min; rivaroxaban administered 1 h prior to andexanet. †Andexanet administered twice daily, every third day, for 13 days; rivaroxaban administered once daily, every third day, for 13 days. cardiovascular examinations or clinical or anatomic pathology related to administration of andexanet (alone or in combination with rivaroxaban) when compared with respective controls. There was no increased incidence of thrombosis relative to vehicle controls, as evidenced by examination of all major organs by H&E as well as PTAH staining. Small changes in hemodynamic parameters were noted, but considered to have no toxicologic significance due to variability and lack of dose-dependence. Antibodies to andexanet were detected in plasma samples in a dose-and time-dependent manner, as expected following administration of a human protein to monkeys. On average, andexanet administration (60 mg kg À1 day
À1
) to rivaroxaban-anticoagulated monkeys demonstrated lower anti-andexanet antibody titers compared with non-anticoagulated monkeys (data not shown). No neutralizing antibody activity was observed, as demonstrated by the expected level of reversal of rivaroxaban anticoagulation measured by anti-FXa activity. In addition, the antibody response did not interfere with the activity of endogenous FX or FXa, as measured by a lack of change in the RVVT coagulation assay (data not shown).
Administration of andexanet was associated with a transient increase in certain coagulation markers (TAT and D-dimer) (Fig. 3) . However, these markers were not associated with any evidence of clot formation or fibrin deposition on histopathological examination (H&E and PTAH) of monkeys at necropsy. Furthermore, the elevation of these blood markers was attenuated when andexanet was co-administrated with rivaroxaban.
Discussion and conclusion
These studies demonstrate the effectiveness of andexanet in reversing the anticoagulant effects of the direct FXa inhibitor, rivaroxaban, in animal models, with promising preclinical PK properties and toxicological safety profile. In a rabbit liver laceration 'treatment' model, andexanet administration in a setting of active visceral bleeding significantly decreased blood loss associated with rivaroxaban anticoagulation. Mitigation of blood loss was associated with dose-dependent decreases in the unbound fraction of rivaroxaban and anti-FXa activity, as well as prolonged clotting times (PT and APTT). As the anticoagulant effect of rivaroxaban is directly related to its unbound fraction and can be quantified by anti-FXa activity, these two measurements were identified as key parameters to monitor reversal of anticoagulation. These are key endpoints in completed as well as ongoing human clinical trials of andexanet [12, 13] . Administration of andexanet caused a substantial redistribution of rivaroxaban from the extravascular to the vascular compartment, where andexanet binds to rivaroxaban with high affinity, and the two highest doses significantly attenuated blood loss as the andexanet concentration was high enough to sequester rivaroxaban from both compartments. The stoichiometry of this sequestration revealed that an~1.3 : 1 ratio of andexanet to total rivaroxaban plasma concentration was sufficient to cause reversal of anticoagulation and reduction in blood loss. This is in remarkably close agreement with the theoretical 1 : 1 stoichiometry of andexanet:rivaroxaban binding, and is consistent with the stoichiometry observed in the Phase 2 clinical studies with apixaban and rivaroxaban [14, 15] .
The PK of andexanet in rats and monkeys showed a small volume of distribution consistent with the intravascular volume, low systemic clearance, and a short distribution half-life followed by a long terminal half-life. Co-administration of rivaroxaban had no impact on andexanet PK parameters, nor did andexanet have effect on rivaroxaban elimination rate. This indicates that rivaroxaban is not cleared when bound to andexanet but that it is cleared separately. Experiments in nephrectomized rats showed that renal clearance was a significant elimination pathway for andexanet in this species. These PK properties may be clinically beneficial in patients by allowing rapid reversal of the FXa inhibitor-induced anticoagulation, and possibly subsequent re-anticoagulation within hours after andexanet clearance.
Prior studies on the pharmacological and toxicological safety of andexanet have shown that it does not affect PT in human plasma, has no effect on thrombin generation in human plasma, and does not affect blood loss on its own in rabbit and rat blood-loss models [9] . Here, we confirmed these findings and extended them under conditions in which andexanet was co-administered with hEGR-Xa in a rat anticoagulation model. EGR-Xa is a well-characterized, catalytically inactive, human FXa molecule that competes with FXa for assembly into the prothrombinase complex with high affinity, and has a potent anticoagulant effect [10, 11, 16] . The addition of a 10-fold excess of andexanet to hEGR-Xa had no additive effect on prolongation of clotting times, suggesting that at the concentrations used in this study, andexanet did not compete with native FXa for binding on the phospholipid surface to form a prothrombinase complex, and thus had no anticoagulant effect.
Repeat administration of andexanet in GLP toxicology studies in cynomolgus monkeys, with or without concomitant rivaroxaban, was well tolerated at the maximum dose evaluated (60 mg kg À1 day
À1
). Compared with andexanet doses used in the human Phase 3 trials, the 60 mg kg À1 day À1 dose in monkeys represents~2-to 3-fold higher plasma concentration. The observation of an anaphylactic reaction on day 13 in a single monkey receiving repeated high-dose andexanet every 3 days is not an unexpected consequence of multiple injections of a foreign protein. There were no other andexanet-related toxicities from the repeated administration of this recombinant human protein in monkeys. There was also no histopathological evidence of andexanet-related thrombosis or perturbation of coagulation markers (PT, APTT and RVVT). These observations are consistent with studies in healthy volunteers, where only a few mild administration site reactions were observed in activetreatment groups, in 9 out of 101 subjects, which usually resolved on their own [12] . In one subject with a history of hives, mild erythematous hives developed, which resolved with diphenhydramine treatment. Finally, consistent with andexanet's short half-life, there was no evidence of accumulation of andexanet between day 1 and 13 in PK analyses. The short distribution half-life of andexanet in monkeys and other animal models is similar to the half-life in humans, which is approximately 45 min. Based on these findings, the no-observedadverse-effect level (NOAEL) for andexanet in monkeys was 60 mg kg À1 day
. One observation from the GLP preclinical toxicity study in cynomolgus monkeys was a dose-dependent transient increase in plasma levels of TAT and D-dimer, markers indicative of increased thrombin generation. Co-administration with rivaroxaban was generally associated with lower TAT and D-dimer plasma concentrations compared with andexanet alone. These transient increases may be attributable to the interaction of andexanet (a derivative of FXa) with tissue factor pathway inhibitor (TFPI), an endogenous inhibitor of FXa [17, 18] . Therefore, all tissues from the vehicle-and high-dose-andexanet-treated monkeys were examined for evidence of thrombosis, but there was no evidence of andexanetrelated fibrin deposition in this study. The magnitude of the TAT and D-dimer increases in the monkey studies is similar to that seen in human Phase 2 and 3 studies, where healthy subjects have also shown no evidence of thrombotic events after receiving andexanet [12] . Similarly, clinical trials evaluating a TFPI-binding antibody, concizumab, also showed elevations in coagulation markers (prothrombin fragments 1 and 2 and D-dimer) without evidence of thrombotic events [19] . Further studies are under way to understand the andexanet-TFPI interaction, as well as the interaction between andexanet and other coagulation proteins such as protein C/protein S.
In summary, andexanet demonstrated preclinical effectiveness for the reversal of rivaroxaban-induced anticoagulation in the setting of acute blood loss in animal models. These experiments have elucidated many of the PK consequences (e.g. redistribution of rivaroxaban from an extravascular compartment back into the vascular compartment) and pharmacological requirements (e.g. decrease in the unbound fraction of rivaroxaban and consequent decrease in anti-FXa activity) of reversing direct FXa inhibitor-induced anticoagulation that can be expected in a clinical situation. These results suggest that andexanet has the potential to become a specific and well-tolerated reversal agent for FXa inhibitors, as shown in Phase 2 [14, 15] and 3 studies [12] in subjects anticoagulated with rivaroxaban, apixaban, edoxaban or enoxaparin. Finally, these preclinical findings on the ability of andexanet to reduce blood loss are consistent with its hemostatic efficacy reported in an interim assessment of an ongoing Phase 3b/4 study in anticoagulated patients with acute major bleeding [13] . 
